Ovarian Cancer Awareness Month takes place in March 2023. The aim is to increase knowledge around ovarian cancer, in self-checks, early diagnosis, research, and support. It is in this spirit that Frontiers in Immunology is launching this new article collection to coincide with this awareness day. This occasion not only offers an opportunity to acknowledge Ovarian Cancer Awareness Month but also to consider the importance of open-access research in improving survival rates. While immunotherapies have demonstrated impressive response rates in other cancers, ovarian cancer patients typically do not benefit from existing immunotherapeutic approaches. As such, we are creating an article collection focused on opportunities to improve immunotherapy outcomes in ovarian cancer.
We welcome manuscripts that aim to tackle the challenges facing ovarian cancer immunotherapy, this includes but is not limited to the following sub-topics:
• Immune suppression and immunometabolism within the ovarian tumor microenvironment.
• Therapeutic strategies to modulate the ovarian tumor microenvironment and overcome barriers to antitumor immunity.
• Rational combination approaches (eg. Checkpoint inhibitors, PARP inhibitors, chemotherapy) to increase the efficacy of immunotherapy.
• The role of B cells (or therapeutic modalities related to B cells) in preventing tumor growth in ovarian cancer.
• Development of ovarian cancer vaccines.
• Emerging cell therapies in ovarian cancer.
• New and emerging immune biomarkers in Ovarian Cancer.
This Research Topic accepts Original Research, Reviews, and Mini-Reviews, and aims to address and offer new insights focussing on immunotherapy-specific approaches to ovarian cancer treatment. Manuscripts lacking an immunological focus will be out of scope for this Research Topic.
We also take this opportunity to thank the wider community for their continued efforts in allowing for accelerated scientific developments within the ovarian cancer immunotherapy field, and most importantly, for working with us on our mission to make science open.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Ovarian Cancer Awareness Month takes place in March 2023. The aim is to increase knowledge around ovarian cancer, in self-checks, early diagnosis, research, and support. It is in this spirit that Frontiers in Immunology is launching this new article collection to coincide with this awareness day. This occasion not only offers an opportunity to acknowledge Ovarian Cancer Awareness Month but also to consider the importance of open-access research in improving survival rates. While immunotherapies have demonstrated impressive response rates in other cancers, ovarian cancer patients typically do not benefit from existing immunotherapeutic approaches. As such, we are creating an article collection focused on opportunities to improve immunotherapy outcomes in ovarian cancer.
We welcome manuscripts that aim to tackle the challenges facing ovarian cancer immunotherapy, this includes but is not limited to the following sub-topics:
• Immune suppression and immunometabolism within the ovarian tumor microenvironment.
• Therapeutic strategies to modulate the ovarian tumor microenvironment and overcome barriers to antitumor immunity.
• Rational combination approaches (eg. Checkpoint inhibitors, PARP inhibitors, chemotherapy) to increase the efficacy of immunotherapy.
• The role of B cells (or therapeutic modalities related to B cells) in preventing tumor growth in ovarian cancer.
• Development of ovarian cancer vaccines.
• Emerging cell therapies in ovarian cancer.
• New and emerging immune biomarkers in Ovarian Cancer.
This Research Topic accepts Original Research, Reviews, and Mini-Reviews, and aims to address and offer new insights focussing on immunotherapy-specific approaches to ovarian cancer treatment. Manuscripts lacking an immunological focus will be out of scope for this Research Topic.
We also take this opportunity to thank the wider community for their continued efforts in allowing for accelerated scientific developments within the ovarian cancer immunotherapy field, and most importantly, for working with us on our mission to make science open.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
